Cancer Research Communications | American Association for Cancer Research

Skip Nav Destination

Editors-In-Chief

Elaine R. Mardis, PhD
Nationwide Children's Hospital
The Ohio State University

Lillian L. Siu, MD
Princess Margaret Cancer Centre
University of Toronto

SUBMIT TO JOURNAL EDITORS

Editors-In-Chief

Elaine R. Mardis, PhD
Nationwide Children's Hospital
The Ohio State University

Lillian L. Siu, MD
Princess Margaret Cancer Centre
University of Toronto

SUBMIT TO JOURNAL EDITORS

Editors' Corner

Striving for Equitable Outcomes in Oncology Patient Care with a Focus on Health Disparities and Outcomes Research

The AACR Annual Meeting 2022 was held April 8-13, 2022 and was attended by more than nineteen thousand attendees (onsite and virtual). The theme of this year’s meeting was Decoding Cancer Complexity...(read more)

Journal Sections

Cancer Research Communications welcomes high-quality research spanning the full spectrum of cancer science and medicine. This open access journal expands the AACR journal portfolio, stimulates the exchange of new ideas and approaches, and provides a rapid publication pathway. The below sections reflect the breadth of this new journal’s scope.

Molecular and Cellular Biology

Tumor Biology

Immuno-oncology

Emerging Technologies and Data Science

Therapeutic Research and Development

Precision Medicine and Biomarkers

Clinical Research and Trials

Epidemiology and Prevention

Health Disparities and Outcomes Research

Featured Articles

Molecular and Cellular Biology

Loss of vascular endothelial glutaminase inhibits tumor growth and metastasis, and increases sensitivity to chemotherapy

Verra M. Ngwa, Deanna N Edwards et al.

Glutamine is the most abundant non-essential amino acid in blood stream; yet it's concentration in tumor interstitium is markedly lower than that in the serum, reflecting the huge demand of various cell types in tumor microenvironment for glutamine. While many studies have investigated glutamine metabolism in tumor ...

Browse Section

Go to Section

Tumor Biology

Loss of vascular endothelial glutaminase inhibits tumor growth and metastasis, and increases sensitivity to chemotherapy

Verra M. Ngwa, Deanna N Edwards et al.

Browse Section

Go to Section

Immuno-oncology

A TCR-like CAR promotes sensitive antigen recognition and controlled T cell expansion upon mRNA vaccination

Matthias Birtel, Ralf-Holger Voss et al.

Chimeric antigen receptor (CAR) T cells are efficacious in patients with B cell malignancies, while their activity is limited in patients with solid tumors. We developed a novel heterodimeric TCR-like CAR (TCAR) designed to achieve optimal chain pairing and integration into the T cell CD3 signaling complex. The TCAR ...

Browse Section

Go to Section

Emerging Technologies and Data Science

Chemical, molecular, and single cell analysis reveal chondroitin sulfate proteoglycan aberrancy in fibrolamellar carcinoma

Adam B. Francisco, Jine Li et al.

Fibrolamellar carcinoma (FLC) is an aggressive liver cancer with no effective therapeutic options. The extracellular environment of FLC tumors is poorly characterized and may contribute to cancer growth and/or metastasis. To bridge this knowledge gap, we assessed pathways relevant to proteoglycans, a major component of ...

Browse Section

Go to Section

Therapeutic Research and Development

8-Azaadenosine and 8-Chloroadenosine are not Selective Inhibitors of ADAR

Kyle A. Cottrell, Luisangely Soto-Torres et al.

The RNA editing enzyme ADAR is an attractive therapeutic target for multiple cancers. Through its deaminase activity, ADAR edits adenosine to inosine in double-stranded RNAs. Loss of ADAR in some cancer cell lines causes activation of the type I IFN pathway and the PKR translational repressor, leading to inhibition of ...

Browse Section

Go to Section

Precision Medicine and Biomarkers

Comprehensive Immunoprofiling of High-Risk Oral Proliferative and Localized Leukoplakia

Glenn J. Hanna, Alessandro Villa et al.

Oral leukoplakia is common and may, in some cases, progress to carcinoma. Proliferative leukoplakia is a progressive, often multifocal subtype with a high rate of malignant transformation compared with the more common localized leukoplakia. We hypothesized that the immune microenvironment and gene expression patterns ...

Browse Section

Go to Section